Mr. Kim Oishi reports

RAKOVINA THERAPEUTICS ANNOUNCES APPOINTMENT OF PROFESSOR PETRA HAMERLIK TO ITS BOARD OF DIRECTORS

Rakovina Therapeutics Inc. has appointed Prof. Petra Hamerlik to its board of directors at the company's annual general meeting of shareholders held on Aug. 18, 2026, in Toronto, Ont. (see news release dated Aug. 19, 2026).

Prof. Hamerlik is the chair of translational neuro-oncology at the University of Manchester. She has served on Rakovina's scientific advisory board (SAB) since Nov. 20, 2023. Prof. Hamerlik previously served as principal scientist and CNS (central nervous system) cancer bioscience lead at AstraZeneca PLC, where she contributed to the development of brain-penetrant DNA repair inhibitors for primary brain tumours and brain metastases. Before AstraZeneca, she was the group leader of the brain tumour biology laboratory at the Danish Cancer Research Centre and associate professor at the University of Copenhagen, where her research included the combination of PARP and HDAC inhibition in the treatment of cancer.

"Prof. Hamerlik brings scientific leadership in the DNA damage response and neuro-oncology to the company's board," said Kim Oishi, chief executive officer of Rakovina Therapeutics. "Her blend of academic and industry expertise is invaluable as Rakovina advances brain-penetrant DDR inhibitor programs toward the clinic."

"The progress that Rakovina has made using AI [artificial intelligence] to advance the development of brain-penetrant DNA-damage response inhibitors has been encouraging," said Prof. Hamerlik. "Rakovina's three programs align with my focus on brain cancer research and my work on PARP inhibitors. I look forward to continuing to contribute as a director as these programs move forward."

"Petra has been a great collaborator since joining our SAB in 2023, so her appointment to the board is a natural next step," said Prof. Mads Daugaard, president and chief scientific officer of Rakovina Therapeutics. "She brings academic leadership in neuro-oncology together with industry experience in developing brain-penetrant DNA repair inhibitors. That combined perspective will sharpen how we prioritize and translate our science."

The company's board of directors consists of Mr. Oishi, Frank Holler, Dr. David Kideckel, Yevgeniy Meshcherekov and Prof. Hamerlik.

About Prof. Petra Hamerlik, PhD

Prof. Hamerlik is chair of translational neuro-oncology at the University of Manchester, where she has established a research team focused on the biology of malignant brain tumours and approaches for their early detection. She previously held a joint appointment as principal scientist and CNS cancer bioscience lead at AstraZeneca, where she contributed to the development of brain-penetrant DNA repair inhibitors for targeting primary brain tumours and brain metastases. Prior to AstraZeneca, Prof. Hamerlik was group leader for the brain tumour biology laboratory within the Danish Cancer Research Centre and associate professor at the University of Copenhagen.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. The company's work is based on unique technologies for targeting the DNA damage response powered by artificial intelligence (AI) using validated, proprietary platforms. By using AI, Rakovina Therapeutics can review and optimize drug candidates at a much greater pace than ever before.

The company has established a pipeline of distinctive DNA damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.

We seek Safe Harbor.